{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:19:34Z","timestamp":1792405174765,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neurofibrillary tangles, consisting of intracellular accumulations of the protein tau, are a hallmark feature of Alzheimer\u2019s disease (AD), and are thought to contribute to neuronal dysfunction and death during the disease process. The quantification of tau proteins in cerebrospinal fluid (CSF) or plasma has enormous utility for AD diagnosis; however, validated non-invasive measures of tau protein are lacking and would have added value for widespread screening. In this study, we quantified the levels of total tau (t-tau), along with neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), in saliva samples from 111 participants, including those with CSF biomarker-confirmed AD, mild AD, non-AD cognitively impaired (CI) and cognitively unimpaired (CU) older adults, using immunoassays on the Meso Scale Discovery platform. We find that salivary levels of t-tau were significantly elevated in AD and mild AD, but not other CI patients, compared to CU adults, while salivary levels of NfL and GFAP showed no significant differences across cohorts. In addition, we found that salivary t-tau was significantly correlated with CSF biomarker measures, including significant positive correlations with CSF t-tau and p-tau 181 (0.257;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.016 and 0.276;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009 for t-tau and p-tau 181, respectively). Salivary t-tau was also found to predict AD cases compared to CU individuals with an area under the curve of 0.834 (95% CI 0.74\u20130.93;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Finally, we observed that salivary t-tau levels were significantly negatively correlated with cognitive performance in AD patients, as well as all individuals together. These findings suggest that salivary t-tau might represent a non-invasive biomarker specific to AD pathology and could aid in early detection of AD or for clinical screening purposes.\n                  <\/jats:p>","DOI":"10.1007\/s00415-026-13651-1","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:00:56Z","timestamp":1771430456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Salivary total tau: a clinically practical measure of tau neuropathology in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"273","author":[{"given":"Alison R.","family":"Bamford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Theresa","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv C.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Yassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Shankle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2024-4710","authenticated-orcid":false,"given":"Elizabeth A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"0 1","key":"13651_CR1","first-page":"S405","volume":"33 Suppl 1","author":"RJ Caselli","year":"2013","unstructured":"Caselli RJ, Reiman EM (2013) Characterizing the preclinical stages of Alzheimer\u2019s disease and the prospect of presymptomatic intervention. J Alzheimers Dis 33 Suppl 1(0 1):S405\u2013S416","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"13651_CR2","doi-asserted-by":"publisher","first-page":"830","DOI":"10.2967\/jnumed.121.263694","volume":"63","author":"M Malpetti","year":"2022","unstructured":"Malpetti M, Joie R, Rabinovici GD (2022) Tau beats amyloid in predicting brain atrophy in Alzheimer disease: implications for prognosis and clinical trials. J Nucl Med 63(6):830\u2013832","journal-title":"J Nucl Med"},{"key":"13651_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.neuron.2011.04.009","volume":"12","author":"M Morris","year":"2011","unstructured":"Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 12:410\u2013426","journal-title":"Neuron"},{"issue":"13","key":"13651_CR4","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.3390\/ijms23137307","volume":"23","author":"S Holper","year":"2022","unstructured":"Holper S, Watson R, Yassi N (2022) Tau as a biomarker of neurodegeneration. Int J Mol Sci 23(13):7307","journal-title":"Int J Mol Sci"},{"issue":"6","key":"13651_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med 284(6):643\u2013663","journal-title":"J Intern Med"},{"issue":"4","key":"13651_CR6","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y et al (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146(4):1592\u20131601","journal-title":"Brain"},{"issue":"3","key":"13651_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, Langhough RE, Cody K et al (2024) Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol 81(3):255\u2013263","journal-title":"JAMA Neurol"},{"issue":"4","key":"13651_CR8","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H, Scheffler M, Assal F et al (2024) Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol 271(4):2053\u20132066","journal-title":"J Neurol"},{"key":"13651_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ibneur.2023.03.004","volume":"14","author":"M Sabaei","year":"2023","unstructured":"Sabaei M, Rahimian S, Haj Mohamad Ebrahim Ketabforoush A, Rasoolijazi H, Zamani B, Hajiakhoundi F, Soleimani M, Shahidi G et al (2023) Salivary levels of disease-related biomarkers in the early stages of Parkinson\u2019s and Alzheimer\u2019s disease: a cross-sectional study. IBRO Neurosci Rep 14:285\u2013292","journal-title":"IBRO Neurosci Rep"},{"key":"13651_CR10","doi-asserted-by":"publisher","first-page":"577744","DOI":"10.1016\/j.jneuroim.2021.577744","volume":"361","author":"G Katsipis","year":"2021","unstructured":"Katsipis G, Tzekaki EE, Tsolaki M, Pantazaki AA (2021) Salivary GFAP as a potential biomarker for diagnosis of mild cognitive impairment and Alzheimer\u2019s disease and its correlation with neuroinflammation and apoptosis. J Neuroimmunol 361:577744","journal-title":"J Neuroimmunol"},{"key":"13651_CR11","first-page":"53","volume":"11","author":"H Pekeles","year":"2019","unstructured":"Pekeles H, Qureshi HY, Paudel HK, Schipper HM, Gornistky M, Chertkow H (2019) Development and validation of a salivary tau biomarker in Alzheimer\u2019s disease. Alzheimers Dement (Amst) 11:53\u201360","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"13651_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/brainsci12050595","volume":"12","author":"Y Cui","year":"2022","unstructured":"Cui Y, Zhang H, Zhu J, Liao Z, Wang S, Liu W (2022) Investigation of whole and glandular saliva as a biomarker for Alzheimer\u2019s disease diagnosis. Brain Sci 12(5):595","journal-title":"Brain Sci"},{"issue":"10","key":"13651_CR13","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1007\/s00784-020-03214-7","volume":"24","author":"A Tvarijonaviciute","year":"2020","unstructured":"Tvarijonaviciute A, Zamora C, Ceron JJ, Bravo-Cantero AF, Pardo-Marin L, Valverde S, Lopez-Jornet P (2020) Salivary biomarkers in Alzheimer\u2019s disease. Clin Oral Investig 24(10):3437\u20133444","journal-title":"Clin Oral Investig"},{"issue":"2","key":"13651_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3233\/JAD-2011-110731","volume":"27","author":"M Shi","year":"2011","unstructured":"Shi M, Sui YT, Peskind ER, Li G, Hwang H, Devic I, Ginghina C, Edgar JS et al (2011) Salivary tau species are potential biomarkers of Alzheimer\u2019s disease. J Alzheimers Dis 27(2):299\u2013305","journal-title":"J Alzheimers Dis"},{"key":"13651_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neurobiolaging.2018.06.014","volume":"70","author":"NJ Ashton","year":"2018","unstructured":"Ashton NJ, Ide M, Scholl M, Blennow K, Lovestone S, Hye A, Zetterberg H (2018) No association of salivary total tau concentration with Alzheimer\u2019s disease. Neurobiol Aging 70:125\u2013127","journal-title":"Neurobiol Aging"},{"issue":"5","key":"13651_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/alzrt212","volume":"5","author":"T Skillb\u00e4ck","year":"2013","unstructured":"Skillb\u00e4ck T, Zetterberg H, Blennow K, Mattsson N (2013) Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. Alzheimers Res Ther 5(5):47","journal-title":"Alzheimers Res Ther"},{"issue":"10510","key":"13651_CR17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(25)01294-2","volume":"406","author":"GB Frisoni","year":"2025","unstructured":"Frisoni GB, Hansson O, Nichols E, Garibotto V, Schindler SE, van der Flier WM, Jessen F, Villain N et al (2025) New landscape of the diagnosis of Alzheimer\u2019s disease. Lancet 406(10510):1389\u20131407","journal-title":"Lancet"},{"issue":"4","key":"13651_CR18","first-page":"653","volume":"24","author":"B Reisberg","year":"1988","unstructured":"Reisberg B (1988) Functional assessment staging (FAST). Psychopharmacol Bull 24(4):653\u2013659","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"13651_CR19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41598-023-28019-y","volume":"13","author":"GM Parkin","year":"2023","unstructured":"Parkin GM, Corey-Bloom J, Snell C, Smith H, Laurenza A, Daldin M, Bresciani A, Thomas EA (2023) Salivary Huntingtin protein is uniquely associated with clinical features of Huntington\u2019s disease. Sci Rep 13(1):1034","journal-title":"Sci Rep"},{"issue":"2","key":"13651_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00415-024-12785-4","volume":"272","author":"AR Bamford","year":"2025","unstructured":"Bamford AR, Parkin GM, Corey-Bloom J, Thomas EA (2025) Comparisons of neurodegenerative disease biomarkers across different biological fluids from patients with Huntington\u2019s disease. J Neurol 272(2):158","journal-title":"J Neurol"},{"issue":"7","key":"13651_CR21","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.1016\/j.tjpad.2025.100216","volume":"12","author":"AR Bamford","year":"2025","unstructured":"Bamford AR, Adams JN, Kim S, Taylor LM, Tuteja N, McMillan LC et al (2025) Salivary levels of amyloid beta reflect brain amyloid beta burden in cognitively-normal older adults. J Prev Alzheimers Dis 12(7):100216","journal-title":"J Prev Alzheimers Dis"},{"key":"13651_CR22","doi-asserted-by":"publisher","first-page":"e44278","DOI":"10.7554\/eLife.44278","volume":"8","author":"JN Norwood","year":"2019","unstructured":"Norwood JN, Zhang Q, Card D, Craine A, Ryan TM, Drew PJ (2019) Anatomical basis and physiological role of cerebrospinal fluid transport through the murine cribriform plate. Elife 8:e44278","journal-title":"Elife"},{"key":"13651_CR23","doi-asserted-by":"publisher","first-page":"137330","DOI":"10.1016\/j.neulet.2023.137330","volume":"810","author":"Y Hamsafar","year":"2023","unstructured":"Hamsafar Y, Chen Q, Borowsky AD, Beach TG, Serrano GE, Sue LI, Adler CH, Walker DG et al (2023) Biochemical analyses of tau and other neuronal markers in the submandibular gland and frontal cortex across stages of Alzheimer disease. Neurosci Lett 810:137330","journal-title":"Neurosci Lett"},{"issue":"2","key":"13651_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/WCO.0000000000000904","volume":"34","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Cullen NC, Mattsson-Carlgren N, Hansson O (2021) Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer\u2019s disease. Curr Opin Neurol 34(2):266\u2013274","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"13651_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9(2):197\u2013210","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"13651_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"issue":"1","key":"13651_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321","journal-title":"N Engl J Med"},{"issue":"12","key":"13651_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM (2023) Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19(12):715\u2013736","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"13651_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","volume":"12","author":"FH Duits","year":"2016","unstructured":"Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lle\u00f3 A, Hausner L, Molinuevo JL, Stomrud E et al (2016) Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 12(2):154\u2013163","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13651-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:04:59Z","timestamp":1773785099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13651-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13651"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13651-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.A.Y. is the Co-founder and Chief Scientific Officer of Augnition Labs, LLC. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the University of California, Irvine, Institutional Review Board, in accordance with the requirements of the Code of Federal Regulations on the Protection of Human Subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided their written informed consent to participate in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No AI of any kind was used in preparing this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"149"}}